-

MedinCell’s Long-Acting Injectable to Fight Malaria Ready to Enter Regulatory Development

MedinCell and the project consortium members, IRD, IRSS and CIRDES, have successfully designed, tested, and confirmed with Unitaid the selection of the lead formulation. Regulatory preclinical activities are starting with the objective of a first clinical trial in 2023.

MONTPELLIER, France--(BUSINESS WIRE)--MedinCell and the consortium members have conducted an in vivo proof of concept on cattle that showed a 3-month mosquitocidal effectiveness of an injectable long-acting formulation of Ivermectin based on the proprietary BEPO® technology.

The investigational product mdc-STM aims at reducing the transmission of the parasite responsible for Malaria, thanks to a killing effect on the vector mosquitoes when they bite treated people.

Malaria remains one of the main health threats worldwide with more than 200 million people infected yearly.

In March 2020, global health agency Unitaid granted MedinCell with a $6.4 million subvention over three years to conduct the formulation and preclinical activities of the program.

mdc-STM benefits from synergies with other MedinCell’s programs based on Ivermectin all of them using different formulation and doses fitted to their specific indications.

Access the complete press release.

About MedinCell

MedinCell is a clinical stage pharmaceutical company that develops a portfolio of long-acting injectable products in various therapeutic areas by combining its proprietary BEPO® technology with active ingredients already known and marketed. Through the controlled and extended release of the active pharmaceutical ingredient, MedinCell makes medical treatments more efficient, particularly thanks to improved compliance, i.e. compliance with medical prescriptions, and to a significant reduction in the quantity of medication required as part of a one-off or chronic treatment. The BEPO® technology makes it possible to control and guarantee the regular delivery of a drug at the optimal therapeutic dose for several days, weeks or months starting from the subcutaneous or local injection of a simple deposit of a few millimeters, fully bioresorbable. Based in Montpellier, MedinCell currently employs more than 140 people representing over 25 different nationalities.

www.medincell.com

Contacts

MedinCell
David Heuzé
Head of communication
david.heuze@medincell.com
+33 (0)6 83 25 21 86

NewCap
Louis-Victor Delouvrier
Relations investisseurs
medincell@newcap.eu
+33 (0)1 44 71 94 94

NewCap
Nicolas Merigeau
Media Relations
medincell@newcap.eu
+33 (0)1 44 71 94 94

MedinCell

BOURSE:MEDCL

Release Versions

Contacts

MedinCell
David Heuzé
Head of communication
david.heuze@medincell.com
+33 (0)6 83 25 21 86

NewCap
Louis-Victor Delouvrier
Relations investisseurs
medincell@newcap.eu
+33 (0)1 44 71 94 94

NewCap
Nicolas Merigeau
Media Relations
medincell@newcap.eu
+33 (0)1 44 71 94 94

More News From MedinCell

Medincell Increases the Amount Allocated to the Liquidity Contract with Rothschild Martin Maurel

MONTPELLIER, France--(BUSINESS WIRE)--Regulatory News: In order to accompany the increase in the volumes of shares traded daily, Medincell (Paris:MEDCL) signed on April 11, 2025 an amendment to the Liquidity Agreement entered into with Rothschild Martin Maurel on September 10, 2024, in accordance with the provisions of Regulation (EU) No. 596/2014 of the European Parliament and of the Council of April 16, 2014, Commission Delegated Regulation (EU) 2016/908 of February 26, 2016, Articles L. 225-...

Medincell’s Partner Teva Presented Phase 3 Survey Results Demonstrating Patient and Healthcare Professional Satisfaction with Olanzapine LAI

MONTPELLIER, France--(BUSINESS WIRE)--Regulatory News: Medincell (Paris:MEDCL): More than 92% of schizophrenia patients taking Olanzapine LAI in the Phase 3 SOLARIS survey were satisfied or very satisfied with the initiation regimen, dosing schedule and trial medication1. Richard Malamut, Chief Medical Officer at Medincell, commented: “Patient and healthcare professional satisfaction with treatment options is critical to successfully managing schizophrenia. In addition to positive efficacy resu...

Medincell Strengthens its Board of Directors to Support its Growth

MONTPELLIER, France--(BUSINESS WIRE)--Regulatory News: Medincell (Paris:MEDCL): Pascal Touchon joins the Board of Directors 40 years of international experience in the biopharmaceutical industry, holding operational and strategic leadership positions, and serving on the boards of both American and European companies, Former Global Head of Strategy and Business Development then Global Head of the Cell & Gene division at Novartis Oncology, where he led the development and global launch of the...
Back to Newsroom